Answers are grounded in this paper and cite their sources.
With the increasing prevalence of refractory multidrug-resistant Gram-negative bacterial infections, the development of novel antibacterials targeting Gram-negative pathogens has become an urgent priority. The complex cell envelope structure of these bacteria, particularly the lipopolysaccharide (LPS)-containing outer membrane, presents a major barrier to drug penetration and efficacy, driving extensive research on outer membrane-targeting strategies. While progress has been rapid, a focused narrative synthesis of the field remains valuable. This review provides a comprehensive narrative overview of antibacterial strategies directed against Gram-negative bacteria, spanning from fundamental design principles to specific applications. It begins by outlining the structural features of the Gram-negative bacterial envelope that underpin resistance, then surveys and discusses key development approaches—including de novo design and structural modification of existing agents. Within this framework, the mechanisms of action and recent advances of various antibacterial classes are examined and evaluated. In particular, unresolved challenges remain in understanding drug metabolic behavior, mitigating toxicity, and improving the translational efficiency from preclinical design to clinical application. Addressing these issues will likely depend on the coordinated integration of fundamental mechanistic insights, rational drug design strategies, and complete pharmaceutical technologies, ultimately facilitating the development of antibacterial therapies capable of delaying resistance evolution and enabling more precise pathogen eradication.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: